Expand all sections

Ipilimumab

Yervoy

Extended indication Extension of indication to include in combination with nivolumab the treatment of adult patients wit
Therapeutic value No estimate possible yet
Registration phase No registration expected

Product

Active substance Ipilimumab
Domain Oncology
Reason of inclusion Indication extension
Main indication Lung cancer
Extended indication Extension of indication to include in combination with nivolumab the treatment of adult patients with unresectable stage III NSCLC
Proprietary name Yervoy
Manufacturer BMS
Portfolio holder BMS
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Orphan drug No
Registration phase No registration expected
Additional remarks No EMA submission (https://news.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-CheckMate--73L-Trial/default.aspx)

Therapeutic value

Current treatment options Durvalumab
Therapeutic value No estimate possible yet
Substantiation Er zal mogelijk substitutie plaatsvinden met durvalumab. Er wordt verwacht dat bij oudere patiënten wel gepast gebruik zal plaatsvinden door de mogelijke toxiciteit van de ipi-nivo combinatie behandeling na radiotherapie.

Expected patient volume per year

Patient volume

< 2,231

Market share is generally not included unless otherwise stated.
References NKR 2021 (1); Expert opinie (2)
Additional remarks In 2021 werden er 2.231 patiënten gediagnosticeerd met de indicatie stadium 3 NSCLC. Er wordt echter verwacht dat het volume lager zal uitvallen doordat niet alle oudere patiënten deze behandeling zullen krijgen (2).

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.